ASTRO Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma Guideline: A Case-Based Discussion

World Health Organization (WHO) grade 4 adult-type diffuse glioma remains one of the most challenging malignancies to treat, demanding a multidisciplinary and evidence-based approach. The role of radiation therapy (RT) has evolved since the publication of the 2016 ASTRO Guideline on Radiation Therapy for Glioblastoma with this guideline serving as a replacement. This activity provides an in-depth overview of the updated guidance, highlighting key changes in molecular diagnostics, RT protocols and systemic therapies. Attendees gain practical insight for implementing the guideline, with case-based discussions demonstrating how to tailor treatment strategies to individual patients. Emphasis is also placed on optimizing care pathways and fostering collaboration among neurosurgeons, neuro-oncologists, radiation oncologists and supportive care teams to enhance outcomes. This activity is essential for clinicians seeking to stay at the forefront of WHO grade 4 diffuse glioma management and ensure their patients benefit from the latest evidence-based strategies. Whether you are a seasoned specialist or new to neuro-oncology, this educational activity will equip you with actionable knowledge to improve patient care in this rapidly evolving field.

Topics:

  1. WHO Grade 4 Adult Type Glioma Guideline: Overview and Introduction
    Debra Nana Yeboa, MD
  2. Indications for RT and/or Adjuvant Therapies in Patients with Newly Diagnosed Grade 4 Adult-Type Diffuse Glioma
    Kristin J. Redmond, MD, MPH
  3. Dose-fractionation Regimens for RT After Biopsy/Resection in Patients with WHO Grade 4 Adult-Type Diffuse Glioma 
    Jonathan Knisely, MD, FASTRO
  4. Appropriate Target Volumes and Techniques for RT in Patients with WHO Grade 4 Adult-Type Diffuse Glioma
    Mary Frances McAleer, MD, PhD
  5. Indications and Appropriate Techniques for Reirradiation
    Christina Tsien, MD, FASTRO
  6. Key Takeaways and Future Directions
    Joseph A. Bovi, MD
  7. Q and A
    Debra Nana Yeboa, MD – Moderator
    Full Panel

This activity is available from June 16, 2026, through 11:59 p.m. Eastern time on June 15, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, pathologists, radiation therapists, radiation dosimetrists, residents, patients and patient advocates.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss indications and appropriate techniques for reirradiation in patients with grade 4 diffuse gliomas whose disease recurs following completion of standard first-line therapy.
  • Identify indications for postoperative RT and postoperative chemoradiation and discuss the evidence for appropriate dose-fractionation regimens for external beam radiation therapy (EBRT) after biopsy/resection in patients with WHO grade 4 adult-type diffuse gliomas and how treatment might vary based on pretreatment characteristics.   
  • Discuss appropriate target volumes and techniques for definitive EBRT. 
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
06/16/2026
Course expires: 
06/15/2028
Cost:
$149.00
Rating: 
0

Moderator:  

  • Debra Nana Yeboa, MD, is employed by The University of Texas MD Anderson Cancer Center. Dr. Yeboa receives grant/research funding from the Brockman Foundation, MD Anderson Institution, Novartis and Robert Wood Johnson. 
  • Speakers:
  • Kristin J. Redmond, MD, MPH, is employed by Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Dr. Redmond receives grant/research funding from Accuray, Canon, Elekta AB and Icotec. Dr. Redmond receives compensation/payment from Biomimetix, Gamma tile and Icotec.  
  • Joseph A. Bovi, MD, is employed by Thedacare and the Medical College of Wisconsin. Dr. Bovi receives compensation/payment from Imaging Biometrics.  
  • Jonathan Knisely, MD, FASTRO, is employed by NewYork-Presbyterian/Weill Cornell Medicine and Yale University. Dr. Knisely receives travel expenses from GT MedTech.  
  • Mary Frances McAleer, MD, PhD, is employed by MD Anderson Cancer Center. Dr. McAleer has no relevant financial relationship with ineligible companies to disclose. 
  • Christina Tsien, MD, FASTRO, is employed by McGill University Health Centre. Dr. Tsien has no relevant financial relationship with ineligible companies to disclose.

Planners:

  • Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 
     

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until June 15, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.